Neurofibromatosis-1 (NF1) is one of the most common hereditary multisystemic disorders. The disease manifests a variety of characteristic features that include: hyperpigmentary abnormalities of the skin (café-au-lait macules, freckles in the axillae, and iris Lisch nodules) and growth of benign peripheral nerve sheath tumors (neurofibromas) in the skin. Associated extracutaneous clinical features include: skeletal abnormalities, neurological, cardiovascular, endocrine and other malformations. NF1 is caused by mutation in the neurofibromatosis-1 gene, which codes for the protein neurofibromin. The inheritance of NF1 follows an autosomal dominant trait, although about 50% of patients present with new („de novo“) mutations, and represent the first member of their family. No difference in the severity of the disease can be found in patients with familial mutations versus those with new mutations. We present a 78-year-old female patient with an extreme cutaneous form of neurofibromatosis who reported no affected family member. Apart from skin problems, she had no major health issues in childhood and adolescence, but in recent decades she had frequent headaches, occasional abdominal pain, and vision and hearing impairment. About 10 to 14 days before admission, she developed a severe cough, shortness of breath, and chest and abdominal pain. On examination, the patient of short stature (hight: 152 cm, weight: 49 kg) presented with thousands of soft nodules dispersed over the whole body, except on extensor sides of thighs and lower legs; the nodules varied in color from skin-colored, livid erythematous, to brown-grey; the nodules on the abdomen were moist, partly bleeding from the base, and accompanied by an unpleasant odor. Her feet were also densely covered by dark purple lumps, with dystrophic changes of the toe nails that were thickened, frayed, and yellowish. The skeletal abnormalities included: short stature, severe osteoporosis and osteosclerosis of the head bone structure; degenerative arthropathc-spondylotic changes of the thoracolumbar spine segment with signs of diffuse skeletal hyperostosis; pronounced degenerative changes of the lumbar spine. CT scans of the head, chest and abdomen showed the following abnormalities: flattening of the paraventricular gyri and reduction of brain parenchyma with hypodensity of the white matter in terms of cortical atrophy; periventricular bilateral small post-ischemic microvascular brain lesions of varying chronicity; in the parenchyma of the upper left lung lobe the apical presence of small areas of pleural effusion with consequent subatelectic region; distended stomach and a small inner wall herniation; hypotrophic right kidney; atherosclerotic lesions of the abdominal aorta; low grade infrarenal kinking of the abdominal aorta. Pathohistological analysis of biopsy specimen taken from the nodule corresponded with cutaneous neurofibroma. Consultative examinations of various specialists pointed to the existence of the following comorbidities: obstructive respiratory syndrome and right lobe pneumonia that were treated by antibiotics, aminophylline and dexamethasone infusions; psycho-organic syndrome without focal neurological deficit; Lisch nodules in each eye, and senile cataract. Considering the age and medical presentation of the patient, no other treatment was considered. In conclusion, this is a sporadic case of cutaneous neurofibromatosis 1 in a 78-year-old female patient who presented with extremely severe cutaneous neurofibromas, making this case at least rather peculiar.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Irvine AD Mellerio JE. Genetics and genodermatoses. In: Burns T Breathnach S Cox N Griffiths C editors. Rook’s textbook of dermatology. 8th ed. Oxford: Blackwell Publishing Ltd; 2010. p. 15.1-15.97.
2. Sehgal VN Verma P Chatterjee K. Type 1 neurofibromatosis (von Recklinghausen disease). Cutis 2015;96(3):E23-6.
3. von Recklinghausen F. Uber die Multiplen Fibrome der Haut und Ihre Beziehung Zu Den Multiplen Neuromen. Berlin: August Hirschwald; 1882.
4. Crowe FW Schull WJ Neel JV. A clinical pathological and genetic study of multiple neurofibromatosis. Springfield IL: Charles C Thomas; 1956.
5. Boyd KP Korf BR Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;1(1):1–16.
6. Jouhilahti EM Peltonen S Heape AM Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178(5):1932–9.
7. Laycock-van Spyk S Thomas N Cooper DN Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics 2011;5(6):623–90.
8. Diggs-Andrews KA Gutmann DH. Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci 2013;36(4):237–47.
9. Fox CJ Tomajian S Kaye AJ Russo S Abadie JV Kaye AD. Perioperative management of neurofibromatosis type 1. Ochsner J 2012;12(2):111–21.
10. Ferner RE Huson SM Thomas N Moss C Willshaw H Evans DG et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44(2):81–8.
11. Gabriele AL Ruggieri M Patitucci A Magariello A Conforti FL Mazzei R et al. A novel NF1 gene mutation in an Italian family with neurofibromatosis type 1. Childs Nerv Syst 2011;27(4):635-8.
12. Allouche J Bellon N Saidani M Stanchina-Chatrousse L Masson Y Patwardhan A et al. In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells. Proc Natl Acad Sci USA 2015;112(29):9034–9.
13. Shah KN. The diagnostic and clinical significance of café-au-lait macules. Pediatr Clin North Am 2010;57(5):1131-53.
14. Tchernev G Chokoeva AA Patterson JW Bakardzhiev I Wollina U Tana C. Plexiform neurofibroma- a case report. Medicine (Baltimore) 2016;95(6):e2663.
15. Staser K Yang FC Clapp DW. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu Rev Pathol 2012;7:469–95.
16. O’Brien DE Brenner DS Gutmann DH Gereau RW. Assessment of pain and itch behavior in a mouse model of neurofibromatosis type 1. J Pain 2013;14(6):628–37.
17. Korf BR. Statins bone and neurofibromatosis type 1. BMC Med 2008;6:22
18. Arun KP Joseph T Jaishankar HP Abhinethra MS. Von Recklinghausens disease: a series of four cases with variable expression. J Maxillofac Oral Surg 2015;14(1):161–7.
19. Rodriguez FJ Perry A Gutmann DH O’Neill BP Leonard J Bryant S et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008;67(3):240–9.
20. Klein-Tasman BP Janke KM Luo WL Casnar CL Hunter SJ Tonsgard JT et al. Cognitive and psychosocial phenotype of young children with neurofibromatosis-1. J Int Neuropsychol Soc 2014;20(1):88–98.
21. Gutmann DH Parada LF Silva Aj Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci 2012;32(41):14087–93.
22. Madubata CC Olsen MA Stwalley DL Gutmann DH Johnson KJ. Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis. Genet Med 2015;17(1):36–42.
23. Licis AK Vallorani A Gao F Chen C Lenox J Yamada KA et al. Prevalence of sleep disturbances in children with neurofibromatosis type 1. J Child Neurol 2013;28(11):1400–5.
24. Agaimy A Vassos N Croner RS. Gastrointestinal and retroperitoneal manifestations of neurofibromatosis type 1 (Recklinghausen’s disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol 2012;5(9):852–62.
25. Salvi P Lorenzon L Caterino S Antolino L Antonelli MS Balducci G. Gastrointestinal stromal tumors associated with neurofibromatosis 1: a single centre experience and systematic review of the literature including 252 cases. Int J Surg Oncol 2013;2013:398570.
26. Hersh JH. Health supervision for children with neurofibromatosis. Pediatrics 2008;121(3):633–42
27. Zografos GN Vasiliadis GK Zagouri F Aggeli C Korkolis D Vogiaki S et al. Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Oncol 2010;8:14.
28. Lodish MB Stratakis CA. Endocrine tumours in neurofibromatosis type 1 tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab 2010;24(3):439–49.
29. Cunha KS Rozza-de-Menezes RE Luna EB Almeida LM Pontes RR Almeida PN et al. High prevalence of hyposalivation in individuals with neurofibromatosis 1: a case–control study. Orphanet J Rare Dis 2015;10:24.
30. Friedman JM Arbiser J Epstein JA Gutmann DH Huot SJ Lin AE et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002;4(3):105–11.
31. Oderich GS Sullivan TM Bower TC Gloviczki P Miller DV Babovic-Vuksanovic D et al. Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum management and results. J Vasc Surg 2007;46(3):475–84.
32. Duong TA Sbidian E Valeyrie-Allanore L Vialette C Ferkal S Hadj-Rabia S et al. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis 2011;6:18.
33. Park SJ Sawitzki B Kluwe L Mautner V Holtkamp N Kurtz A. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med 2013;11:109.
34. Karajannis MA Ferner RE. Neurofibromatosis–related tumors: emerging biology and therapies. Curr Opin Pediatr 2015;27(1):26–33.
35. Walker L Thompson D Easton D Ponder B Ponder M Frayling I et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006;95(2):233–8.